✦ LIBER ✦

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

✍ Scribed by Shen, Lin; Li, Jin; Xu, Jianming; Pan, Hongming; Dai, Guanghai; Qin, Shukui; Wang, Liwei; Wang, Jinwan; Yang, Zhenzhou; Shu, Yongqian; Xu, Ruihua; Chen, Lei; Liu, Yunpeng; Yu, Shiying; Bu, Lilian; Piao, Yongzhe

Book ID: 121545843
Publisher: Springer
Year: 2014
Tongue: English
Weight: 784 KB
Volume: 18
Category: Article
ISSN: 1436-3291
DOI: 10.1007/s10120-014-0351-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rationale and Design of MARQUEE: A Phase

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

✍ Giorgio V. Scagliotti; Silvia Novello; Joan H. Schiller; Vera Hirsh; Lecia V. Se 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 332 KB

A phase II study of weekly docetaxel and

A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer

✍ Li, C-P; Chen, J-S; Chen, L-T; Yen, C-J; Lee, K-D; Su, W-P; Lin, P-C; Lu, C-H; T 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 286 KB

TRIO-012: A Multicenter, Multinational,

TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally Recurrent or Metastatic Breast Cancer

✍ John Mackey; Karen Gelmon; Miguel Martin; Nicole McCarthy; Tamas Pinter; Mathieu 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 156 KB

3LBA SOLTI-0701: A double-blind, randomi

3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC)

✍ J. Baselga; J.G.M. Segalla; H. Roché; A. del Giglio; E.M. Ciruelos; S. Cabral Fi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB